JP2005517025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517025A5 JP2005517025A5 JP2003566523A JP2003566523A JP2005517025A5 JP 2005517025 A5 JP2005517025 A5 JP 2005517025A5 JP 2003566523 A JP2003566523 A JP 2003566523A JP 2003566523 A JP2003566523 A JP 2003566523A JP 2005517025 A5 JP2005517025 A5 JP 2005517025A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- reagents
- cell population
- polyclonality
- shift
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35539102P | 2002-02-08 | 2002-02-08 | |
| US37573302P | 2002-04-26 | 2002-04-26 | |
| PCT/US2003/005850 WO2003067221A2 (en) | 2002-02-08 | 2003-02-07 | Compositions and methods for restoring immune responsiveness in patients with immunological defects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010226115A Division JP2011036264A (ja) | 2002-02-08 | 2010-10-06 | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517025A JP2005517025A (ja) | 2005-06-09 |
| JP2005517025A5 true JP2005517025A5 (cg-RX-API-DMAC7.html) | 2006-03-23 |
Family
ID=27737495
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003566523A Ceased JP2005517025A (ja) | 2002-02-08 | 2003-02-07 | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
| JP2010226115A Pending JP2011036264A (ja) | 2002-02-08 | 2010-10-06 | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010226115A Pending JP2011036264A (ja) | 2002-02-08 | 2010-10-06 | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20040005298A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1472341A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005517025A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003216436A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2474186A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200307129A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003067221A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| CA2539716A1 (en) * | 2003-09-22 | 2005-04-07 | Xcyte Therapies, Inc. | Compositions and methods to accelerate hematologic recovery |
| US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| WO2006021955A2 (en) * | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
| US20060286089A1 (en) * | 2005-04-08 | 2006-12-21 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| WO2008016431A2 (en) * | 2006-07-29 | 2008-02-07 | Robert Lamar Bjork | Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug |
| WO2010099205A1 (en) | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
| CA2791975C (en) | 2010-02-04 | 2021-02-09 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
| EP2518504A1 (en) * | 2011-04-29 | 2012-10-31 | Miltenyi Biotec GmbH | A method for the quantitative and qualitative characterization of antigen-specific T cells recognizing a specific antigen |
| BR102013020194A2 (pt) * | 2012-08-31 | 2014-10-29 | Gm Global Tech Operations Inc | Estrutura de posicionamento e reforço para um veículo, conjunto da extremidade dianteira para um veículo, e, veículo |
| EP2711418B1 (en) * | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| AU2014302771A1 (en) * | 2013-06-24 | 2016-01-28 | Celgene Corporation | Methods of expanding T cells |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| WO2015148512A1 (en) | 2014-03-24 | 2015-10-01 | Qt Holdings Corp | Shaped articles including hydrogels and methods of manufacture and use thereof |
| US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| EP3091032A1 (en) * | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US9790467B2 (en) | 2015-09-22 | 2017-10-17 | Qt Holdings Corp | Methods and compositions for activation or expansion of T lymphocytes |
| AU2017305948B2 (en) | 2016-08-01 | 2023-12-14 | Academia Sinica | Internally fixed lipid vesicle |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58117537A (ja) * | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US5081029A (en) * | 1985-09-25 | 1992-01-14 | Oncogen | Methods of adoptive immunotherapy for treatment of aids |
| US6071517A (en) | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5057423A (en) | 1987-12-18 | 1991-10-15 | University Of Pittsburgh | Method for the preparation of pure LAK-active lymphocytes |
| US6010902A (en) * | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5837447A (en) * | 1992-04-15 | 1998-11-17 | Blood Center Research Foundation, Inc., The | Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69433970T2 (de) | 1993-08-10 | 2005-08-11 | W.L. Gore & Associates, Inc., Newark | Zelleinkapselungsvorrichtung |
| JPH09510201A (ja) | 1994-03-07 | 1997-10-14 | メダレツクス・インコーポレーテツド | 臨床的効用を有する二重特異性分子 |
| WO1995033823A1 (en) | 1994-06-03 | 1995-12-14 | The United States Of America, Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of t cells |
| US5827642A (en) * | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JPH10503964A (ja) | 1995-06-07 | 1998-04-14 | ゴア ハイブリッド テクノロジーズ,インコーポレイティド | 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法 |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| DE69739951D1 (de) * | 1996-03-04 | 2010-09-16 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
| CA2278847A1 (en) * | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US6867041B2 (en) * | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) * | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| AU779289B2 (en) * | 2000-05-25 | 2005-01-13 | Xcyte Therapies, Inc. | Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression |
| US20050226857A1 (en) * | 2001-06-01 | 2005-10-13 | Xcyte Therapies, Inc. | T cell therapy for the treatment of cachexia and chronic diseases |
| US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
-
2003
- 2003-02-07 JP JP2003566523A patent/JP2005517025A/ja not_active Ceased
- 2003-02-07 WO PCT/US2003/005850 patent/WO2003067221A2/en not_active Ceased
- 2003-02-07 US US10/360,507 patent/US20040005298A1/en not_active Abandoned
- 2003-02-07 EP EP03737733A patent/EP1472341A4/en not_active Withdrawn
- 2003-02-07 EP EP08172864.4A patent/EP2034009B1/en not_active Expired - Lifetime
- 2003-02-07 CA CA002474186A patent/CA2474186A1/en not_active Abandoned
- 2003-02-07 TW TW092102522A patent/TW200307129A/zh unknown
- 2003-02-07 AU AU2003216436A patent/AU2003216436A1/en not_active Abandoned
-
2007
- 2007-01-25 US US11/627,279 patent/US20070274974A1/en not_active Abandoned
-
2008
- 2008-11-07 AU AU2008243157A patent/AU2008243157A1/en not_active Ceased
-
2009
- 2009-09-09 US US12/556,282 patent/US20100092436A1/en not_active Abandoned
-
2010
- 2010-10-06 JP JP2010226115A patent/JP2011036264A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69503903D1 (de) | Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung | |
| JP2006502416A5 (cg-RX-API-DMAC7.html) | ||
| DE69230146D1 (de) | Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung | |
| JP2007510622A5 (cg-RX-API-DMAC7.html) | ||
| JP2002513156A5 (cg-RX-API-DMAC7.html) | ||
| JP2003527832A5 (cg-RX-API-DMAC7.html) | ||
| JP5753775B2 (ja) | 化学合成した核酸の純度を測定する方法と組成物 | |
| JP2012107019A5 (cg-RX-API-DMAC7.html) | ||
| JP2008503720A5 (cg-RX-API-DMAC7.html) | ||
| CA2406240A1 (en) | Hcv anti-core monoclonal antibodies | |
| JP2009518039A5 (cg-RX-API-DMAC7.html) | ||
| CY1110689T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
| JP2008518884A5 (cg-RX-API-DMAC7.html) | ||
| JP2002518460A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505634A5 (cg-RX-API-DMAC7.html) | ||
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2004528574A5 (cg-RX-API-DMAC7.html) | ||
| WO2005092926A3 (en) | Reducing the risk of human and anti-human antibodies through v gene manipulation | |
| CY1115295T1 (el) | Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w | |
| JP2004532839A5 (cg-RX-API-DMAC7.html) | ||
| ATE464374T1 (de) | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen | |
| WO2005113000A3 (en) | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody | |
| JP2007526908A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531716A5 (cg-RX-API-DMAC7.html) | ||
| CY1110144T1 (el) | Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα |